Biotech News

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Aziyo Biologics (AZYO)Aziyo Biologics2026-10-01 20:46 ESTCompany update

Boston Scientific released the full $8 million holdback on schedule and with no claims Escrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestiture The Company is now fully funded through the

Aziyo Biologics

Drug-Eluting Biomatrix Company Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site. Antibiotic-Eluting Platform The company's biomatrix technology incorporates antibiotics into a biologic scaffold. The platform was first...

Recent company news

AZYOAziyo Biologics2026-10-01 20:46 EST

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029

Related news

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

Aziyo Biologics

Recent company news